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Abstract Even students who reject evolution are often
willing to consider cases in which evolutionary biology
contributes to, or undermines, biomedical interventions.
Moreover, the intersection of evolutionary biology and
biomedicine is fascinating in its own right. This review
offers an overview of the ways in which evolution has
impacted the design and deployment of live-attenuated
virus vaccines, with subsections that may be useful as
lecture material or as the basis for case studies in classes at
a variety of levels. Live-attenuated virus vaccines have
been modified in ways that restrain their replication in a
host so that infection (vaccination) produces immunity but
not disease. Applied evolution, in the form of serial passage
in novel host cells, is a “classical” method to generate live-
attenuated viruses. However, many live-attenuated vaccines
exhibit reversion to virulence through back-mutation of
attenuating mutations, compensatory mutations elsewhere
in the genome, recombination or reassortment, or changes
in quasispecies diversity. Additionally, the combination of
multiple live-attenuated strains may result in competition or
facilitation between individual vaccine viruses, resulting in
undesirable increases in virulence or decreases in immuno-
genicity. Genetic engineering informed by evolutionary
thinking has led to a number of novel approaches to
generate live-attenuated virus vaccines that contain sub-
stantial safeguards against reversion to virulence and that
ameliorate interference among multiple vaccine strains.
Finally, vaccines have the potential to shape the evolution
of their wild-type counterparts in counter-productive ways;
at the extreme, vaccine-driven eradication of a virus may
create an empty niche that promotes the emergence of new
viral pathogens.
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Overview
Even students who balk at the very mention of the word
evolution can often be persuaded to consider examples of
microbial evolution, and thus to become familiar with the
processes common to all biological evolution. Having
experienced the inescapable logic of the theory of evolution
through these “non-threatening” examples, such skittish
students are sometimes then willing to accept the role of
evolution in the diversification of other forms of life.
Students are often especially receptive to learning how
evolution can be used to generate beneficial organisms for
biomedicine and biotechnology, a subset of the more
general category of “applied evolution” (Bull and Wichman
2001), as well as how evolution can sabotage biomedical
interventions (e.g., evolution of antibiotic resistance, http://
www.pbs.org/wgbh/evolution/library/10/4/l_104_03.html).
In the following review, I focus on the role of evolution
in the successes and failures of one such intervention: live-
attenuated virus vaccines. These vaccines are live viruses
that have been modified in ways that restrain their
replication in a host so that infection (vaccination) produces
immunity but not disease (Moser and Leo 2010). Thus,
killed and protein subunit vaccines are excluded from
consideration, as are vectored vaccines in which an
immunogenic protein from one virus is inserted into
another species of virus (Girard et al. 2006; Durbin and
Whitehead 2010). Many of the vaccines currently licensed
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for use in humans, including the Sabin oral poliovirus
vaccine (OPV), the combined measles-mumps-rubella
vaccine, and the chickenpox (varicella virus) vaccine, are
composed of live-attenuated viruses (Table 1). These
vaccines have been a tremendous boon to human health
(e.g., Widdowson et al. 2009; Roush and Murphy 2007;
Zhou et al. 2005; Levine and Robins-Browne 2009, but see
(Francis 2010) for some of the failures and inequities in
vaccine deployment). To list just a few examples, variola
virus, the agent of smallpox, has been eradicated from the
world, poliovirus is approaching global eradication
(Nathanson and Kew 2010), measles virus has been
eliminated from the United States (Roush and Murphy
2007) (but see, Centers for Disease Control and Prevention
2011), and the incidence of chickenpox has dropped
dramatically in the United States (Hambleton and Gershon
2005). However, live-attenuated vaccines are not without
their risks, which derive primarily from the further
evolution of vaccine viruses themselves, as well as the
impact of vaccine-driven immunity on the evolution of their
wild-type counterparts.
My intention here is to explore both the positive and
negative impacts of evolution on the success of live-
attenuated virus vaccines and thereby provide cases of
microbial evolution with great relevance to human health. I
have used many of the subsections below, modified to
incorporate appropriate levels of detail, in a wide variety of
college classes ranging from Introductory Biology for Non-
Majors through to Advanced Virology. Students have found
them useful and interesting in their own right and I have
often used them as an entrée to a more general overview of
evolutionary theory.
Applied Evolution: Generating Live-Attenuated
Vaccines by Serial Passage
To date, all live virus vaccines licensed for use in humans
in the United States (Table 1) have been generated by one
of two “classical” approaches: (a) the Jennerian approach,
first utilized by Edward Jenner, in which a related virus
from a non-human animal is used to protect against a
human virus or (b) the Pastorian approach, first employed
by Louis Pasteur, of serial passage (Fig. 1a) (Bazin 2003).
Both methods leverage the evolutionary principle that
fitness is always specific to a particular environment, and
thus high fitness in one environment may come at a cost of
low fitness in another.
In serial passage, adaptations that enhance replication of
a virus in a novel host or environmental condition may lead
to attenuated replication in the natural host or condition.
Adaptation is accomplished by infecting a live animal or a
flask of cultured cells with a wild-type virus, allowing the
virus to replicate until it reaches a useful concentration,
harvesting the virus, and then using these progeny virions
to initiate another infection in a new animal or culture
(Fig. 1a). Pasteur was the first to use this technique,
passaging rabies virus in rabbits in order to attenuate it for
dogs and humans (Plotkin 2011). Most subsequent live-
attenuated viruses have also been generated by passage
through a novel host or hosts. The vaccine for yellow fever
virus, a pathogen that is maintained in African and South
American primates under natural conditions, was created
via passage through Asian macaques, mouse embryo
tissues and chick embryo tissues (Fig. 1b). The vaccine
for measles virus, which in nature exclusively infects
humans, was generated by passage through chick embryo
cells (Anonymous 1980), and the vaccine for varicella,
another virus that infects only humans during natural
transmission, was achieved through passage in guinea pig
cells (Fig. 1b). Additionally, adaptation to replication at
lower temperatures is often a desirable evolutionary
outcome. The cold-adapted influenza virus was passaged
in chicken kidney cells in temperatures descending from 36
to 25°C (Fig. 1b), with the goal of generating a virus that
could replicate in the upper respiratory tract but not deeper
in the lungs (Maassab and DeBorde 1985).
Because evolution relies on the random occurrence and
subsequent spread of rare beneficial mutations, the number
of passages and the number of conditions needed to achieve
satisfactory attenuation varies considerably (Fig. 1b). For
example, the varicella vaccine virus was generated by just
28 passages in three different cell lines, while the yellow
fever vaccine required hundreds of passages in five
different conditions (Fig. 1b). At first blush, it may seem
startling that viruses can undergo substantial evolution in
just ten or twenty passages. However, viral evolution is
Table 1 Live-attenuated virus vaccines currently licensed for use in
the United States (www.fda.gov)
Live-attenuated virus(es) Trade name
Adenovirus types 1 and 4 None
Influenza Flumist
Measles Attenuvax
Measles and mumps M-M-Vax
Measles, mumps and rubella M-M-R II
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known to proceed at a breakneck pace due to the unique
features of viral genetics and viral population dynamics
(Moya et al. 2004; Domingo et al. 2008).
Viruses have genomes composed of RNA or DNA. Due
to the lack of proofreading in RNA-dependent RNA
polymerases, RNA viruses have extraordinarily high rates
of mutation. The average RNA virus genome experiences
one mutation per 10,000 nucleotides per replication, a rate
of mutation almost a million times faster than the average
bacterial genome (Sanjuan et al. 2010). Additionally RNA
genomes tend to be very small, ten kilobases or less (Moya
et al. 2004), and thus on average RNA genomes accumulate
approximately one mutation per genome per replication.
The rate of mutation in RNA genomes is so high that RNA
viruses may exist as a quasispecies, a swarm of related
genetic variants whose interactions determine attributes of
the population (Lauring and Andino 2010). DNA viruses
show a much greater range in genome size, from 3.2
kilobases (hepatitis B virus; Liang 2009) to 1.2 megabases
(mimivirus; Claverie et al. 2009). Intriguingly, the rate of
mutation in DNA viruses shows an inverse correlation with
genome size, and small single-stranded DNA genomes may
mutate at a rate comparable to RNA genomes (Sanjuan et
al. 2010; Duffy et al. 2008). The pace of adaptation
depends not only on genomic mutation rate but also on
the rate of replication and final population size of those
genomes (Moya et al. 2004). Most viruses replicate rapidly
within their hosts and some can achieve quite staggering
population sizes: for example, three days after an infectious
mosquito bite, West Nile virus reaches titers greater than
1011 plaque-forming units per ml of serum in certain bird
hosts (Komar et al. 2003), a number that greatly exceeds
the seven billion humans currently alive and that is roughly
equivalent to the number of stars in the Milky Way. Thus,
viruses easily outstrip the evolutionary pace of any other
living organism, and this allows the evolution of live-
attenuated vaccines over a relatively small number of serial
passages.
Fig. 1 a The Pastorian approach for attenuation by serial passage b
Passage history of three live-attenuated virus vaccines derived by
serial passage: the yellow fever virus 17D vaccine strain (Monath et
al. 2008), the cold-adapted influenza A/Ann Arbor/6/60 vaccine strain
(Maassab and DeBorde 1985), and the chickenpox (varicella) Oka
vaccine strain (Hambleton and Gershon 2005; Takahashi et al. 2008)
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Vaccines Gone Wild: Reversion to Virulence
in Live-Attenuated Vaccines
In the classical methods of attenuation, a vaccine virus’s
phenotype determines its genotype. Passage proceeds until
satisfactory attenuation is achieved, irrespective of how
many passages or how many mutations this may entail.
Indeed, with the notable exception of the OPV polio
vaccine strains (Kew et al. 2005), the mutations responsible
for the attenuation of most live-attenuated vaccines have
not been fully characterized. However, it is clear that in
some live-attenuated viruses, the number of attenuating
mutations is quite small. Each of the attenuated poliovirus
types 1, 2, and 3 strains in OPV carries only a few (two to
six) major attenuating mutations (Kew et al. 2005). Given
the rapid mutation rates of all viruses, but particularly RNA
viruses, it is not surprising that some vaccine viruses revert
to virulence. About one in every 750,000 children receiving
the first dose of OPV experiences vaccine-associated
paralytic poliomyelitis attributable to reversion of one of
the three strains (Kew et al. 2005). This propensity to revert
is one of the reasons that OPV was replaced with the
inactivated poliovirus vaccine in the United States, hence
OPV is not listed in Table 1. Such reversion may occur as a
result of back-mutation of attenuating mutations, compensa-
tory mutations elsewhere in the genome, or as discussed in the
next section, recombination. Conversely, the more attenuating
mutations in the genome of a live-attenuated vaccine, the less
likely reversion will be. To date, the cold-adapted influenza
vaccine, with attenuating mutations in four of the eight
genome segments (Maassab and DeBorde 1985), has never
reverted to virulence in a vaccinee (Tosh et al. 2008).
Recently, quasispecies heterogeneity per se has also been
implicated in changes in virulence (Kenney et al. 2011;
Sauder et al. 2006). Sauder et al. (2006) passaged mumps
vaccine virus in either monkey kidney or chicken embryo
fibroblast cells. They found that these passaged strains
showed additional attenuation in rats and that this phenotypic
change was associated with changes in quasispecies hetero-
geneity rather than fixation of any individual mutation.
Several factors can increase the likelihood that a live-
attenuated vaccine will revert to virulence. First, the loss of
a subset of attenuating mutations during vaccine manufac-
ture can accelerate reversion. Often the cell lines approved
for vaccine manufacture differ from the cell lines in which
the serial passage of the vaccine was conducted, thus
changing the selection pressures on the virus. Complete
reversion to virulence would be detected during safety
testing and such lots would be eliminated, but if attenuation
is enacted by the epistatic effect of multiple mutations
(Burch et al. 2003), and a subset of these are lost during
vaccine manufacture, then complete reversion would
require fewer subsequent mutations. A recent study by
Victoria et al. (2010) searched for back-mutation of
attenuating mutations in lots of eight live-attenuated virus
vaccines strains, including OPV, using deep sequencing,
and found none. However, previous studies of the OPV
have detected variants lacking particular attenuating muta-
tions in vaccine lots (Kew et al. 2005).
Second, reversion is more likely the longer vaccine virus
replication persists and the higher the virus titer achieved in
an individual vaccinee. Extended replication offers more
mutational fodder and more time for natural selection to
occur within an environment (the host). Such selection is
likely to favor virus variants that replicate to higher titers or
in a greater range of tissue types than the original vaccine
virus; i.e., viruses that are more similar to the wild-type
phenotype. Both overall levels of replication and breadth of
tissue tropism may be positively correlated with virulence.
Valsamakis et al. (1999) experimentally passaged a measles
vaccine virus in human tissues engrafted into mice and
observed reversion to virulence. Moreover OPV has been
shown to replicate to high titers over long periods of time in
some immunodeficient vaccinees, resulting in reversion to
virulence (Kew et al. 2005; Odoom et al. 2008). These
immunodeficient individuals also excrete polioviruses over
long periods of time, increasing the likelihood of fecal-oral
transmission to unvaccinated individuals in the community.
Such transmission from vaccinees to unvaccinated indi-
viduals is a third contributor to reversion to virulence.
Although live-attenuated vaccine transmission was initially
considered a bonus of live vaccines, a “free” vaccination, it is
now clear that person-to-person transmission imposes strong
selection for a return to the wild-type phenotype. Recognizing
this, polio researchers divide vaccine-derived poliovirus
(VDPV) isolates into three categories: (a) iVDPVs derived
from immunodeficient patients, (b) cVDVPs that show
evidence of sustained person-to-person transmission, and (c)
aVDPVs from non-immunodeficient patients or environmen-
tal sources that are not associated with an outbreak (Kew et al.
2005). Predictably, virulent vaccine-derived viruses have
caused substantial outbreaks in countries where so few
children are vaccinated with OPV that herd immunity, the
protection of susceptible individuals that occurs when
pathogen transmission is “short-circuited” by vaccinated
individuals (Fine et al. 2011), is never generated (Kew et
al. 2005). Surprisingly, virulent revertants, presumably
derived from long-term OPV excretors or from contact with
individuals from countries that continue to use OPV, are also
detected in wastewater in countries where only the inacti-
vated poliovirus vaccines is utilized (Roivainen et al. 2010;
Zurbriggen et al. 2008), suggesting that cessation of
vaccination could result in re-emergence of virulent poliovi-
rus in these regions.
OPV is affordable, and vaccination prevents not only
polio disease but also poliovirus transmission, making it
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an excellent vaccine for the eradication of poliovirus.
However, its tendency to slip the leash of attenuation and
spawn virulent, vaccine-derived polioviruses through back-
mutation as well as recombination (discussed below) has led
to the “oral polio vaccine paradox” (Heinsbroek and
Ruitenberg 2010): the same agent that eradicates a disease
may serve to reintroduce it! One solution to this paradox is
a concurrent, worldwide conversion to inactivated polio
vaccine (Heinsbroek and Ruitenberg 2010; Minor 2009),
which would require an unprecedented feat of global
coordination.
Hopeful Monsters: Recombination
Among Live-Attenuated Vaccine Strains
and Between Vaccine and Other Circulating Viruses
In several licensed (Table 1) and candidate (Durbin and
Whitehead 2010) live virus vaccines, multiple strains of a
single species or multiple species are administered concur-
rently. Moreover, vaccine viruses may be administered
simultaneously with a natural infection of a conspecific or
heterospecific virus. Both situations create potential for
recombination between viral genomes. Virus genomes
recombine by one of three general mechanisms: (a) break
and repair in DNA genomes, (b) polymerase template
switching in RNA genomes, and (c) reassortment of
segments in segmented RNA genomes (Condit 2007). All
three mechanisms require co-infection of a single cell by
two different parental genotypes. Because many vaccine
viruses undergo limited replication relative to wild-type
viruses (e.g., Hambleton and Gershon 2005; Monath 2005;
Monath et al. 2008; Whitehead et al. 2007; Condack et al.
2007; Miki and Chantler 1992), it would initially seem
unlikely that more than one virion would enter a given cell.
Moreover, viruses possess a diverse array of mechanisms to
prevent additional viruses from entering an infected cell, a
process known as superinfection exclusion (Zou et al. 2009
and references therein). However, it is increasingly clear
that for some viruses, coinfection occurs at rates greater
than expected by chance when viral density is very low.
Such coinfection enhancement suggests either that a small
fraction of appropriate host cells are actually susceptible to
infection (Dang et al. 2004; Cicin-Sain et al. 2005; Smith et
al. 2008) or that viruses may possess mechanisms to
enhance coinfection at low viral densities (Joseph et al.
2009).
Recombination contributes to the reversion to virulence
and subsequent circulation of OPV strains. Such recombi-
nation can occur between vaccine viruses, between vaccine
and wild-type polioviruses, and between vaccine polio-
viruses and other species of enteroviruses (Kew et al.
2005). Recombination can occur at multiple locations in the
genome, and multiple recombination events can contribute
to the formation of a single genome. An extreme example
of this process is a penta-recombinant VDPV, showing five
crossover sites between types 2 and 3 polio vaccine strains,
that was isolated from a child suffering from poliomyelitis
(Zhang et al. 2010). Recombination between vaccine and
wild-type viruses has also been documented for numerous
virus vaccines for veterinary pathogens, including canine
parvovirus (Mochizuki et al. 2008), infectious bursal
disease virus (He et al. 2009), bovine herpesvirus 1 (Thiry
et al. 2006), and infectious bronchitis virus (Estevez et al.
2003). Recombination is troubling not only for its contri-
bution to virulence, but also because of its potential to
generate entirely new species of viruses—western equine
encephalitis virus, for example, is the product of recombi-
nation between eastern equine encephalitis virus and a
Sindbis-like virus (Weaver et al. 1997; Hahn et al. 1988).
Too Much of a Good Thing: Competition
and Facilitation Among Strains in Multi-Strain Vaccines
Vaccine viruses can exhibit quite different dynamics when
administered in combination with other vaccine viruses
than when administered alone. At one end of the spectrum,
the individual components of a multi-strain vaccine can
show “interference,” in which one or more strains replicate
to lower levels or stimulate a poorer immune response in a
combined vaccine than a single-strain vaccine. Interference
can be the product of immunodominance, direct competi-
tion for cellular or viral replication machinery, or immune-
mediated apparent competition. Such interference has long
been recognized; Sabin and his colleagues (Sabin et al.
1960) pointed out that the individual components of OPV
were more efficacious when administered individually (as
monovalent vaccines) than when administered together in a
trivalent vaccine. Subsequently, multiple instances of
interference among live-attenuated vaccine viruses have
been documented (Nascimento Silva et al. 2011 and
references therein). At the other end of the spectrum,
facilitation, in which the replication or immunogenicity of
attenuated viruses is enhanced in combination, could also
occur. While this phenomenon has not been documented in
vaccine viruses to the best of my knowledge, previous
studies have certainly shown facilitation between unrelated
viruses during concurrent infection (Cicin-Sain et al. 2005;
Agrawal et al. 2002; Allan et al. 2007; Allan et al. 2000),
thus a similar interaction between vaccine viruses is
possible. While the outcomes of interference and facilita-
tion have been described, the mechanisms driving these
dynamics are poorly understood. However, as the number
of new live-attenuated vaccines targeted to the already
overscheduled child continues to increase, it is becoming
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increasingly important to gain a mechanistic understanding
of the ecological interactions among these attenuated
viruses.
Lessons Learned: Evolutionary Considerations
in the Rational Design of Live-Attenuated Vaccines
Reverse genetics has offered a new approach for the
generation of vaccines, namely rational vaccine design. In
this approach, genotype determines virus phenotype.
Potentially attenuating mutations are chosen based on
available knowledge of the molecular biology of the virus.
These mutations are engineered into a recombinant genome
that is inserted into a cell, where it generates a recombinant
virus. The attenuation of the resulting virus is assessed in a
relevant model, and if it is either over- or under-attenuated,
then the mutation may be modified or additional mutations
may be added.
While rational vaccine design is not a case of applied
evolution, to be successful it must be informed by
evolutionary thinking. In particular, due consideration must
be given to preventing reversion to virulence. This may be
ensured by the generation of large mutations (particularly
deletions), numerous mutations with epistatic interactions,
or chimeric viruses in which the structural proteins of a
well-attenuated virus are replaced with those of the virus
targeted for immunization. These strategies have been
employed in the generation of candidate vaccines for
dengue (Durbin and Whitehead 2010) and chikungunya
viruses (Kenney et al. 2011). Alternatively, virus genes
responsible for counteracting host antiviral responses may be
deleted (Kim et al. 2011), or genes in the genome may be
rearranged to deoptimize translation and genome synthesis
(Lim et al. 2006). As an additional safeguard against
reversion, mutations that specifically prevent transmission
may also be sought (e.g., Kim et al. 2011; Hanley et al.
2003). Rational vaccine design may also minimize compe-
tition among multiple strains of the same virus (multivalent
vaccines) by introducing the same mutation into each of the
strains, as has been done with candidate vaccines containing
all four serotypes of dengue virus (Blaney et al. 2006).
In addition, evolutionary thinking has led to novel
approaches to enacting attenuation. As one example,
Vignuzzi et al. (Vignuzzi et al. 2008), reasoning that
quasispecies diversity enhances RNA virus fitness, have
generated polioviruses in which the fidelity of the poly-
merase is significantly enhanced. Not only are such viruses
attenuated, but, because their rate of mutation is lower, they
are less able to revert to a less faithful polymerase. In
another example, researchers have taken advantage of the
tendency of viruses to exhibit codon pair bias: within all of
the options in the degenerate genetic code, viruses tend to
use a subset of pairs of codons to encode specific pairs of
amino acids. Deoptimizing these codon pairs by inserting
different codons that retain the original amino acid
sequence results in attenuated influenza (Mueller et al.
2010) and polioviruses (Coleman et al. 2008). This strategy
involves hundreds of mutations across the genome and has
been called, poetically, “death by a thousand cuts” (Coleman
et al. 2008). Clearly, it will stand as a significant barrier to
reversion to virulence. Thus, evolutionary thinking is leading
to entirely new ways to engineer viral genomes to achieve
attenuation.
Under Pressure: How Selection by Vaccine-Generated
Immunity Can Shape Evolution of Wild-Type Viruses
Viruses evolve in response to natural herd immunity, and it
stands to reason that sufficiently high levels of vaccine-
induced immunity could also shape virus evolution (Boni
2008). Evolution of wild-type viruses in response to
deployment of live-attenuated vaccines has been observed
in several veterinary viruses, including avian metapneumo-
virus (Catelli et al. 2010; Cecchinato et al. 2010) and avian
influenza virus (Park et al. 2011; Lee et al. 2004). The
effects of such vaccine-driven evolution on virus virulence
and transmissibility in unvaccinated animals have yet to be
determined. However, theoretical studies have raised the
concern that “imperfect vaccines,” vaccines that do not
induce sterilizing immunity but rather modulate disease or
transmission, could select for increasing virulence in the
wild-type virus targeted by vaccination (Gandon et al.
2003; Mackinnon et al. 2008; Gandon and Day 2007;
Andre and Gandon 2006; Ganusov and Antia 2006; Massad
et al. 2006). Intriguingly, Manuel et al. (Manuel et al. 2010)
recently reported that imperfect vaccination can prevent
reversion to virulence in a simian-human immunodeficiency
virus (SHIV). They generated a SHIV carrying an attenuating
mutation and then infected both naïve and vaccinated
monkeys with this virus. The attenuated SHIV reverted to
virulence through back-mutation in the naïve, but not the
vaccinated, monkeys. The investigators attribute this effect to
the overall decrease in SHIV replication in the vaccinated
monkeys, suggesting that imperfect vaccines may act as a
brake on the evolution of their wild-type counterparts.
The ultimate goal of many vaccination programs is the
eradication of specific wild-type viruses. This goal has been
achieved for variola virus, the agent of smallpox, is within
reach for poliovirus (Kew et al. 2005) and perhaps measles
virus (Castillo-Solorzano et al. 2011; Moss 2009), and
remains a tempting target for many existing and candidate
vaccine programs. While there is no question that eradica-
tion represents a quantum leap for public health, some
thought must be given to the empty niche that eradication
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creates. Recent increases in monkeypox have been attributed
to the eradication of, and cessation of vaccination against,
smallpox (Rimoin et al. 2010). Moreover, Coxsackie A virus
(Rieder et al. 2001) and sylvatic dengue virus (Vasilakis et al.
2011) could potentially emerge to fill the niches left vacant
should polio and human dengue virus, respectively, be
eradicated. Evolutionary analysis will be needed to predict
the impacts of eradication on future viral emergence.
Conclusion
In 1937, Max Theiler, the father of the yellow fever vaccine,
wrote “One of the most striking phenomena to the student of
virus diseases is the occurrence of variants.” (Theiler and
Smith 1937). Of course evolutionary biologists are equally
fascinated by variants, and it is my hope that this review has
shown how evolutionary biology and vaccinology have been
intertwined since the inception of vaccination and how they
must remain linked for vaccine design and deployment to
proceed safely and effectively. The information and references
herein may be useful for design of lectures or introduction to
case studies that demonstrate the contributions of evolutionary
biology to biomedical advances, including the generation of
most of the virus vaccines in use today and the creation of
novel strategies for vaccine design. This review can also be
used to emphasize the danger of ignoring evolution when
deploying live-attenuated vaccine viruses, since without due
safeguards, evolution may reshape the virulence or transmis-
sibility of these agents. Moreover, virus vaccines themselves
can and have influenced the evolution of naturally occurring
viruses; the consequences of vaccination as a force of
selection will continue to unfold as new vaccines are created
and old vaccines become available to a larger proportion of the
global population.
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